Nephrology Dialysis Transplantation

Journal Information
ISSN / EISSN : 09310509 / 14602385
Current Publisher: Oxford University Press (OUP) (10.1093)
Total articles ≅ 29,897
Google Scholar h5-index: 66
Current Coverage
Archived in

Latest articles in this journal

Faissal Tarrass, Meryem Benjelloun, Omar Benjelloun
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz286

Jimena Cabrera, Mario Fernández-Ruiz, Hernando Trujillo, Esther González, María Molina, Natalia Polanco, Eduardo Hernández, Enrique Morales, Eduardo Gutiérrez, Juan Rodríguez Mori, et al.
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz293

The publisher has not yet granted permission to display this abstract.
Duk-Hee Kang, Yuji Lee, Carola Ellen Kleine, Yong Kyu Lee, Christina Park, Jui-Ting Hsiung, Connie M Rhee, Csaba P Kovesdy, Kamyar Kalantar-Zadeh, Elani Streja
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz296

The publisher has not yet granted permission to display this abstract.
Sunil Bhandari, Philip A Kalra, Mario Berkowitz, Diogo Belo, Lars L Thomsen, Myles Wolf
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfaa011

Abstract:Background The optimal intravenous (IV) iron would allow safe correction of iron deficiency at a single infusion over a short time. The FERWON-NEPHRO trial evaluated the safety and efficacy of iron isomaltoside 1000/ferric derisomaltose (IIM) in patients with non-dialysis-dependent chronic kidney disease and iron deficiency anaemia. Methods In this randomized, open-label and multi-centre trial conducted in the USA, patients were randomized 2:1 to a single dose of 1000 mg IIM or iron sucrose (IS) administered as 200 mg IV injections up to five times within a 2-week period. The co-primary endpoints were serious or severe hypersensitivity reactions and change in haemoglobin (Hb) from baseline to Week 8. Secondary endpoints included incidence of composite cardiovascular adverse events (AEs). Results A total of 1538 patients were enrolled (mean estimated glomerular filtration rate 35.5 mL/min/1.73 m2). The co-primary safety objective was met based on no significant difference in the incidence of serious or severe hypersensitivity reactions in the IIM and IS groups [0.3% versus 0%; risk difference: 0.29% (95% confidence interval: –0.19; 0.77; P > 0.05)]. Incidence of composite cardiovascular AEs was significantly lower in the IIM versus IS group (4.1% versus 6.9%; P = 0.025). Compared with IS, IIM led to a more pronounced increase in Hb during the first 4 weeks (P ≤ 0.021), and change in Hb to Week 8 showed non-inferiority, confirming that the co-primary efficacy objective was met. Conclusions Compared with multiple doses of IS, a single dose of IIM induced a non-inferior 8-week haematological response, comparably low rates of hypersensitivity reactions, and a significantly lower incidence of composite cardiovascular AEs.
Rajiv Agarwal, Patrick Rossignol, Bryan Williams, William B White
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz299

Olivia Boyer, Guillaume Dorval, Aude Servais
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz257

Marleine Mefeugue Siga, Michel Ducher, Nans Florens, Hubert Roth, Nadir Mahloul, Denis Fouque, Jean-Pierre Fauvel
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfz295

The publisher has not yet granted permission to display this abstract.
Federico Nalesso, Francesco Garzotto
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfaa009

Anna Gjerde, Bjørn Steinar Lillås, Hans-Peter Marti, Anna Varberg Reisæter, Bjørn Egil Vikse
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfaa001

The publisher has not yet granted permission to display this abstract.
Emma O’Lone, Martin Howell, Andrea K Viecelli, Jonathan C Craig, Allison Tong, Benedicte Sautenet, William G Herrington, Charles A Herzog, Tazeen H Jafar, Meg Jardine, et al.
Nephrology Dialysis Transplantation; doi:10.1093/ndt/gfaa008

The publisher has not yet granted permission to display this abstract.